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Abstract 
 
Background: Cetuximab is a chimeric monoclonal immunoglobulin antibody inhibitor of the epidermal 
growth factor receptor (EGFR) for the cure of head and neck squamous cell cancer (HNSCC). Cetuximab 
is administered by intravenous infusion once a week, followed by weekly doses. Pharmacodynamics and 
pharmacokinetic studies have demonstrated the bioequivalence of the every-other week (EOW) dosing 
schedule generating greater compliance of the patients and potential economic benefits for the health care 
system. We present the clinical rationale of a different schedule of maintenance Cetuximab after being 
administered concurrently with chemotherapy, in patients diagnosed with recurrent and/or metastatic 
HNSCC; at the same time, we estimated the potential economic benefits on the healthcare budget from a 
societal perspective in Italy. 
 
Methods: A Budget Impact (BI) excel-based model was developed comparing a base case scenario of 100% 
weekly administration with a dose of 250 mg/m2 to an every-other-week (EOW) administration at 50% or 
100% with a dose of 500 mg/m2. A systematic review of epidemiological literature and costs was conducted 
to characterize the population and a 2-4 month therapy time horizon was adopted. Cost of medical 
examinations and patient management as well as indirect costs associated with the loss of productivity have 
been also considered. A one-way and probabilistic sensitivity analysis was performed in order to evaluate 
the robustness of results. 
 
Results: In the base case, the model estimated a total cost of € 4,378,574 versus € 4,031,511 and € 3,684,488 
for the every-other week (EOW) 50% and 100% scenario respectively. Therefore, in the EOW 50% scenario 
it was calculated a cost reduction of €347 thousand of which 70% attributable to indirect costs, increasing 
to €694 thousand after 4 months. Same value at 2 months was obtained for the every-other week (EOW) at 
100% scenario with a further reduction up to €2,13 million after 4 months considering the cost per ampoule 
of drug. 
 
Conclusions: The possible benefits of an every-other week (EOW) schedule in the maintenance phase rely 
on a better compliance of the patients. In our analysis we showed that this simplified schedule could also 
reduce the costs of treatments both for the health system (direct costs) and for the society (indirect costs).  
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Introduction 
Cetuximab is a chimeric monoclonal immunoglobulin G1 (IgG1) antibody inhibitor of 
the epidermal growth factor receptor (EGFR). Due to the substantial benefit in progression-
free survival (PFS) and overall survival (OS) [1, 2], Cetuximab is indicated for the treatment 
of head and neck squamous cell cancer (HNSCC) both in combination with radiotherapy for 
locally advanced disease and with platinum-based chemotherapy for recurrent and/or 
metastatic disease. In all indications, Cetuximab is administered by intravenous infusion 
once a week at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2[3]. 
Although the weekly schedule was validated in clinical studies, the long Cetuximab half-
life of 66-98 hours makes its administration every other week (EOW) theoretically possible.  
Pharmacodynamic (PD) and pharmacokinetic (PK) studies have demonstrated the 
bioequivalence as well as the efficacy of a every other week (EOW) dosing schedule, when 
Cetuximab was employed as a treatment of colorectal cancer [4-7]. Some studies in HNSCC, 
limited to the setting of recurrent and/or metastatic (RM) disease, demonstrated a similar 
profile of toxicities and activity when Cetuximab was employed with an EOW therapeutic 
schedule. In Italy, Cetuximab can be administered alone and every other week (EOW) in 
the maintenance phase after completion of platinum-based and Cetuximab first line 
treatment [6, 8]. Therefore, the benefits of an EOW administration would rely on the greater 
compliance of the patients when the treatment is in maintenance phase and extends over 
time. 
As of today, the clinical rationale for the adoption of an every other week (EOW) 
administration has not been investigated together with the economic consequences on the 
health care system. In particular, due to the scarcity of data in the literature, the budget 
impact of an every other week (EOW) administration schedule for Cetuximab have not been 
assessed from the perspective of the health care service in Italy. 
 
The objective of the present analysis is to present the clinical rationale of a different 
administration method of Cetuximab in patients diagnosed with RM HNSCC together with 
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the economic analysis and the estimation of the potential economic benefits on the 
healthcare budget. 
 
Rationale  
Pharmacokinetic and pharmacodynamic data 
Pharmacokinetic (PK) and pharmacodynamic (PD) for the standard weekly 
Cetuximab and EOW regimens, was evaluated in a phase I study performed in 62 metastatic 
colorectal cancer patients [5]. The study was in two parts: a 6-week Cetuximab monotherapy 
dose-escalation phase and a subsequent combination-therapy phase, during which patients 
received Cetuximab at the same dose/schedule as in the monotherapy phase, combined with 
chemotherapy. Patients in the control group received Cetuximab at a 400 mg/m2 initial dose, 
then 250 mg/m2 each week, whereas patients assigned to the dose-escalation group after the 
initial Cetuximab infusion, received 400–700 mg/m2 EOW. The PK analysis of the different 
treatment groups revealed that the 700 mg/m2 EOW schedule deviated substantially from 
the other dose regimens, with higher trough concentrations in conjunction with delayed 
steady-state conditions, prolonged half-life and reduced clearance. In contrast, trough 
concentration values for the 500 and 600 mg/m2 EOW dosing regimen were comparable to 
the standard weekly regimen. Cetuximab serum concentrations and exposure increased with 
dose. The PK parameters terminal half-life, total plasma clearance and volume of 
distribution at steady state were comparable between the standard weekly and EOW 400, 
500 and 600 mg/m2 dosing regimens. In terms of exposure, the EOW 500 mg/m2 dosing 
regimen matched more similarly the exposure of the 250 mg/m2 weekly schedule. Based on 
these data, the authors concluded that, on the whole, the closest PK match to the weekly 
standard regimen was provided by EOW administration of 500 or 600 mg/m2, with 500 
mg/m2 being the dose of choice in terms of convenience and feasibility. Moreover, 
functional data derived from immunohistochemical analysis of skin biopsies added to the 
PK analysis and provided a biologic rationale supporting the functional equivalence of the 
Cetuximab weekly and EOW dosing regimens. 
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Clinical data 
The safety of the EOW regimen of Cetuximab in RM HNSCC was investigated in a 
phase II study performed in patients with not more than two prior cytotoxic chemotherapy 
regimens, randomized to receive Cetuximab EOW at 500 mg/m2 (n=35) or 750 mg/m2 
(n=26) until disease progression [9]. Escalating the dose to 750 mg/m2 did not appear to 
offer any obvious therapeutic advantage; therefore, this arm was prematurely closed. The 
administration of 500 mg/m2 EOW Cetuximab monotherapy was associated with grade 3/4 
adverse events (AEs) in 48.6% of patients. Acneiform rash was the most common grade 3 
toxicity (11%). This finding resembles the incidence of skin toxicity reported in previous 
studies of standard weekly dosing of Cetuximab, such as the EXTREME study, where grade 
3 or higher skin reactions were reported in 9% [2].  Globally, the overall response rate (ORR) 
was 11.4% among the 35 RM HNSCC patients enrolled in this study and the median PFS 
and OS were 2.2 and 7.0 months, respectively. 
In the maintenance setting, the EOW administration of Cetuximab 500 mg/m2 was 
investigated in 31 RM HNSCC patients after chemotherapy plus weekly Cetuximab as first-
line treatment [10]. The safety of maintenance treatment with EOW Cetuximab was 
evaluated and compared with the occurrence of AEs during the previous combination 
therapy (chemotherapy plus weekly Cetuximab). The rate of any grade 3/4 AEs was 45% 
and 29% in the two groups (EOW Cetuximab versus chemotherapy plus Cetuximab, 
respectively), whereas 16% and 19% of patients experienced grade 3/4 skin rash. In this 
analysis, EOW Cetuximab seemed to be well tolerated and most toxicities decreased with 
time during Cetuximab maintenance compared with combination therapy. No infusion 
reaction was observed with EOW Cetuximab at a dose of 500 mg/m2. 
The administration of Cetuximab and Docetaxel every 2 weeks as first line treatment 
of RM HNSCC was analysed in a retrospective series of 31 patients [11]. The Authors 
showed that grade 3/4 AEs were present in 67.7% of the patients, mainly consisting of 
neutropenia, hypomagnesemia and skin rash, while ORR was 12.9% and median OS and 
PFS were 8.3 and 4 months, respectively. 
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The role of Cetuximab EOW as maintenance therapy was also investigated by [12] 
that have evaluated the efficacy and safety of four cycles of Docetaxel associated with 
Cisplatin and Cetuximab (TPEx) as first-line treatment, followed by maintenance with 
Cetuximab every 2 weeks in patients with RM HNSCC. Fifty-four patients were enrolled, 
with the most common grade 3/4 AEs being skin rash (16.6%) and non-febrile neutropenia 
(20.4%). The primary end point was met with an ORR of 44.4%; median OS and PFS were 
14 and 6.2 months, respectively. 
An observational French study prospectively evaluated a series of 72 patients 
receiving Cetuximab maintenance therapy, which was administered weekly or EOW at 
physician’s discretion [13]. Grade 3/4 skin toxicities were observed in 7.6% of the patients, 
while interestingly the 12-month-PFS rate and 12-month-OS rate did not differ between 
patients treated every 2 weeks or weekly. 
Feasibility of 6 months maintenance Cetuximab after adjuvant concurrent 
chemoradiation plus Cetuximab in HNSCC has also been evaluated by [14]. Maintenance 
Cetuximab started after completion of chemoradiation therapy plus Cetuximab with 500 
mg/m2 every 2 weeks over a 6-month period. Compliance to maintenance Cetuximab was 
quite satisfactory: 80% were still on Cetuximab after 3 and 63% after 5 months; 48% 
completed 6 months maintenance therapy. 
 
Economic consequences 
An excel-based model was developed to estimate the potential economic benefits of  
EOW compared to weekly administration of Cetuximab among patients with RM HNSCC. 
A review of the epidemiological and economic literature was conducted to identify relevant 
information to include in the analysis. The model was then implemented following the 
guidelines suggested by the International Society of Pharmaeconomics and Outcome 
Research (ISPOR) [15, 16].  
7 
 
Comparison Scenarios 
In coherence with the current administration schedule, a base case scenario was set 
considering 100% of patients being treated with a weekly administration of Cetuximab [17]. 
In the comparison scenario the base case administration was replaced with every-other-week 
(EOW) administration at 50% or 100% for the maintenance therapy only. Specifically, in 
the base case scenario the schedule included a dose of 250 mg per body surface area (BSA) 
[17] compared with one dose of 500 mg per BSA every two weeks (alternative scenario). 
Moreover, the expense simulations have been broken down in cost analyses per mg 
of drug used (base case) and per required ampoule (sensitivity analysis). The model assumed 
an average BSA of 1.8 m2 [18]. Details on the treatment schedules are reported in Table 2. 
Epidemiological parameters 
As a first step, the size of the eligible population was identified from the national 
perspective according to the therapeutic indication in Italy. As reported in Table 1, incidence 
rates provided by the Italian Association of Cancer Registries [19] were used to estimate the 
cohort of individuals annually diagnosed with HNSCC cancer. Moreover, it was estimated 
that about 45% of these patients were diagnosed with recurrent and/or metastatic (RM) 
disease [20]. 
Being the model focused on patients treated with Cetuximab alone in the maintenance 
setting, we assumed that about 32% of patients were treated with first line platinum-based 
chemotherapy plus Cetuximab [21] and that the portion undergoing Cetuximab 
monotherapy in maintenance phase was 45% [2]. As a result, the model estimated a cohort 
of patients treated with Cetuximab equivalent to 609 patients a year [2] (Table 1). 
 
Table 1 – Epidemiological parameters to identify the population diagnosed with RM HNSCC treated with 
Cetuximab – Italy 2017 
Epidemiologic Parameters  
Model Parameter 
(%) 
Estimated 
population 
Sources 
Residential population  60,589,445  [22] 
HNSCC Incidence 0.015% 9,300 [19] 
Population with RM HNSCC 45.0% 4,185 [20] 
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Patients treated with Cetuximab 32.3% 1,352 [21] 
Patients undergoing treatment with 
Cetuximab in maintenance phase 
after chemotherapy 
45.0% 609 [2] 
Abbreviations: mCRC: RM HNSCC: recurrent and/or metastatic head and neck squamous cell cancer 
 
The second step concerned the definition of the time horizon to consider in the analysis. Due 
to the limited progression-free survival (PFS) of RM HNSCC, we set a 2-4 month therapy 
time horizon. 
Cost Parameters 
With reference to the estimation of drug cost, the price of Cetuximab has been used 
net of discounts by law and according to the dosing of the two treatment schedules (Table 
2). The model considered both the cost per mg and the cost per ampoule, according to the 
treatment schedules and the ampoules required for an average BSA of 1.8 m2. 
Furthermore, the cost associated with patients’ management was estimated. 
According to this approach, the cost of medical examinations required for drug 
administration and patient management were included in addition to the indirect costs 
associated with the loss of productivity (absence from work) of the patient or caregiver. 
Specifically, the model assumed a cost of €85 per medical examination for each 
administration, including the cost of the physician, nurse, consumption material, for the drug 
administration and distribution by the hospital pharmacy [23]. 
With reference to the indirect costs, the model assumed the loss of a working day 
every time the drug is administered to the patient in the hospital setting. Such assumption 
was based on the hypothesis that, when drug is administered, the whole working day is lost 
either by the patient or the caregiver. Calculations were made considering an average salary 
per hour of €27.8 [24], that corresponded to a daily salary of €200.2 [24, 25] before tax 
(Table 2). 
Finally, the model does not consider efficacy and safety differences between the two 
schedules.  
Table 2 – Parameters of patient definition and therapy cost 
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Parameters of patient definition H&N R/M Parameter Source 
BSA patient, m2 1.8 [18] 
Weekly ampoule CET_weekly/250mg per BSA 5.0 / 450mg [17] 
Weekly ampoule CET_EOW/500mg per BSA 9.0 / 900mg Assumption 
Number of lost working days per medical examination 1.0 Assumption 
Cost parameters Cost Source 
Ampoule price 100  mg € 153.6 AIFA 
Cost of medical examination per administration € 85.0 [23] 
Cost of working day Italy € 200.2 [24, 25] 
Abbreviations: BSA: body surface area; CET: Cetuximab; EOW: every other week. 
Sensitivity Analysis 
Deterministic one-way sensitivity analysis was performed to model the uncertainty of 
the parameters and the consequent variability of the results. Following this approach, the 
results of the budget impact model have been obtained by varying one parameter of the 
model at once, depending on the variability observed in the literature or assumed by the 
authors. Specifically, the following scenarios have been considered: 
 
 RM-HNSCC patients with maintenance treatment with Cetuximab (base case = 
45.0%): Min = 35% - Max 55% 
 Cost of estimated drug by number of ampoules required for the administration (base 
case=cost per mg) 
 Working days lost per visit (base case=1 day lost): Min = 0 – Max = 2 
10 
 
Results: 
The model estimated a total of 609 patients diagnosed with RM-HNSCC and 
subjected to treatment with Cetuximab once a week in the base case scenario. In the next 
paragraphs the comparison between the base case and an EOW administration schedule 
applied to 50% and 100% of the eligible population, is illustrated. 
 
Base case vs EOW 50% Scenario    
Table 3 illustrates the results in terms of budget impact after 2 months, considering 
609 weekly treated patients vs 304 weekly patients and 304 bi-monthly treated patients. 
Considering an average body surface area (BSA) of 1.8 m2, the 2 strategies (weekly 
administration 250 mg per BSA versus EOW 500 mg per BSA) did not differ in terms of 
the cost of the drug per month. The model estimated a cost reduction of €347 thousand, of 
which over 70% was attributable to indirect costs. Administration costs showed a smaller 
saving of approximately €243 thousand (Figure 1). In addition, the model estimated that, 
after 4 months of treatment the cost reduction would increase to €694 thousand. 
 
Table 3 – Budget Impact results, base-case vs EOW 50% Scenario, 2 months 
Cost items Expense 
 Base case (€) 
EOW 50% Scenario 
(€) 
BUDGET IMPACT 
(€) 
Drug cost (calculation per mg) € 2,990,322 € 2,990,322 € 0 
Management cost/administration € 413,808 € 310,356 -€ 103,452 
Indirect costs € 974,445 € 730,833 -€ 243,611 
TOTAL EXPENSE € 4,378,574 € 4,031,511 -€ 347,063 
    
1 Week EOW 50% Scenario 
Tot. no. of treated 
patients 
Base case treated patients 609 0 609 
50% treated patients Scenario 304 304 609 
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Figure 1: Budget Impact results, base-case vs EOW 50% Scenario, per cost item (€)  
 
Abbreviations: RM HNSCC: recurrent and/or metastatic head and neck squamous cell cancer; EOW:every other week 
Base case vs EOW 100% Scenario 
In this scenario the budget impact of EOW strategy was compared with a weekly 
strategy for patients with RM-HNSCC at 2 and 4 months considering same drug expense 
for the two treatment strategies. As a result, the model estimated a cost reduction of €694 
thousand, of which about 70% is due to indirect costs after two months (Table 4, Figure 2). 
After 4 months of treatment the cost reduction would increase to €1,38 million considering 
the cost per mg, and to €2,13 million considering the cost per vial of drug. 
 
Table 4 – Table 3 – Budget Impact results, base-case vs EOW 100% Scenario, 2 months  
Cost items Expense 
 Base case (€) 
EOW 100% Scenario 
(€) 
BUDGET IMPACT (€) 
Drug cost (calculation per mg) € 2,990,322 € 2,990,322 € 0 
Management cost/administration € 413,808 € 206,904 -€ 206,904 
Indirect costs € 974,445 € 487,222 -€ 487,222 
TOTAL EXPENSE € 4,378,574 € 3,684,448 -€ 694,126 
    
1 Week EOW 100% Scenario 
Tot. no. of treated 
patients 
Base case treated patients 609 0 609 
100% treated patients Scenario 0 609 609 
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Figure 2: Budget Impact results, base-case vs EOW 100% Scenario, per cost item (€)  
 
Abbreviations: RM HNSCC: recurrent and/or metastatic head and neck squamous cell cancer; EOW:every other week 
 
Sensitivity analysis results for RM-HNSCC patients 
Figure 3 illustrates the variables with the highest impact on the model results. One-
way sensitivity analysis showed as the model was most sensitive to the number of working 
days lost by patient or caregivers and when the drug cost was per vial instead of mg. (Figure 
3).  
 
Figure 3 –  One-way sensitivity analysis- Case base Budget Impact vs EOW 100% Scenario   
 
Abbreviations: H&N: head and neck; RM HNSCC: recurrent and/or metastatic head and neck squamous cell cancer; EOW: 
every other week   
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Discussion 
In this analysis, we focused on the economic benefit of an EOW administration of 
Cetuximab versus a weekly schedule, as maintenance therapy.  
Patients with RM-HNSCC not amenable to surgical salvage or radiation therapy may 
receive a combination of platinum-based chemotherapy and Cetuximab for a maximum of 
6 cycles, followed by maintenance Cetuximab in case of clinical benefit and good 
tolerability. The weekly schedule of Cetuximab was employed in the pivotal Extreme trial 
and thereby adopted in the clinical practice.  
As confirmed by the PK data, the EOW 500 mg/m2 schedule was similar in terms of 
exposure to the 250 mg/m2 weekly dose; clinical data have confirmed the feasibility and 
activity of this approach, so justifying its broader use. The possible benefits of an EOW 
schedule in the maintenance phase rely on a better compliance of the patients, subject to a 
high number of cycles in the previous months; moreover, this advantage could reflect also 
into a benefit in the quality of life of the patients, receiving endovenous administration 
phased in longer time. 
In our analysis we showed that this simplified schedule could also reduce the costs of 
treatments both for the health system (direct costs) and for the society (indirect costs). The 
latter accounted for the major part of the potential savings following the adoption of an 
EOW administration of Cetuximab in Italy. This result was obtained assuming that after 
chemotherapy and Cetuximab, patients would benefit from an improvement of symptoms 
in the maintenance phase that would allow to gradually resume working.  
Therefore, considering the preclinical and clinical premises and the economic 
benefits, we would suggest that the EOW schedule should be adopted as possible schedule 
of administration of Cetuximab in the maintenance phase, assuming that the disease remains 
controlled and the AEs are well tolerated. 
Some limitations have to be underlined in our analysis. First, the epidemiological 
parameters were based on the data published in national reports, therefore with reference to 
the considered diseases; the number of treated patients with Cetuximab in Italy could be 
either over or under estimated. However, in sensitivity analyses, these variables have been 
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changed in a representative range of the national reality, allowing interval estimates able to 
represent a minimum and maximum impact of plausible expense. 
Secondly, the model may have underestimated the real cost of patients treated with 
RM-HNSCC as it took into account a limited number of cost items. In particular, the model 
considered only the cost of Cetuximab and its administration and indirect costs deriving 
from patient or caregiver’s absence from work not including transportation costs. Also the 
costs due to adverse events and/or disease progression and presenteism or absenteeism for 
adverse events were not included. However, in this case, we assumed they would be 
identical between the two comparisons as confirmed by the therapeutic equivalence both in 
terms of safety and efficacy of the two administration methods of Cetuximab and hence not 
affecting the economic estimation. Finally, we did not include other possible economic 
saving in the EOW schedule, such as the possibility to reduce the drug waste in case of the 
use of the drug contained in vial of fixed dosage, which can be not completely finished. 
Finally, a third limitation is the lack of information on the lost working days in the 
two groups of treatment. The model conservatively assumed that the patients or caregivers 
lost at least one working day. However data may be underestimated due to the risk of adverse 
events causing absence or reduced productivity or even a permanent exit from the labour 
market. In addition, caregivers could be also involved for an extra day after the day of the 
treatment. 
In conclusion, the model represents a first attempt to quantify the economic impact of 
a change in treatment schedules of Cetuximab in Italy. Following the clinical rationale for 
its adoption, the analysis assessed the potential impact of an EOW administration from a 
societal perspective in which indirect costs resulted as the main driver. However, the new 
treatment strategy would also free resources in terms of lower hospital admissions that may 
be efficiently reallocated to maximize the work/hours of hospital staff and therefore have a 
positive impact from the hospital perspective. 
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